Sagimet Biosciences Inc

Explore Sagimet Biosciences’ promising FASN‑inhibitor drugs for NASH, acne, and cancer, and examine its current financial challenges and market prospects.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company pioneering new therapeutics for non-alcoholic steatohepatitis (NASH), acne, and cancer through its innovative FASN inhibitors.

Sagimet Biosciences Inc.’s stock price surged after a Phase 3 trial of its acne treatment, Denifanstat, showed statistically significant and clinically meaningful improvements compared to a placebo.